Ashland delivered first-quarter fiscal 2026 sales of $386 million, reflecting modest declines driven largely by the Avoca divestiture and softer demand in Specialty Additives. Despite a net loss, the company generated strong operating cash flow and narrowed its full-year adjusted EBITDA outlook.

Ashland reported a challenging third quarter of fiscal year 2025, with sales declining 15% to $463 million, largely impacted by portfolio optimization initiatives. The company posted a substantial net loss of $742 million, primarily due to a $706 million non-cash goodwill impairment charge. Despite these headwinds, Ashland delivered Adjusted EBITDA generally in line with expectations, supported by strong margins from cost savings and operational discipline.

Ashland reported a decrease in sales and net income in the second quarter of fiscal year 2025 compared to the prior year, significantly impacted by portfolio optimization initiatives. Despite a mixed demand environment, the company saw momentum in its cost savings program and anticipates accelerated financial impact from cost reduction and manufacturing optimization initiatives in the second half of the fiscal year.

Ashland reported sales of $405 million, a 14% decrease compared to the prior-year quarter. The company experienced a net loss of $165 million, or $3.50 per diluted share. Adjusted EBITDA was $61 million, down 13% from the prior-year quarter. The company is maintaining its full-year fiscal 2025 outlook.

Ashland reported a one percent increase in sales to $522 million for the fourth quarter of fiscal year 2024. Net income rose to $16 million, and adjusted EBITDA increased by 68 percent to $124 million, primarily due to sales and production volume recovery, improved product mix, and deflationary raw materials. The company issued its outlook for full-year fiscal 2025 and provided an update on portfolio optimization.

Ashland reported Q3 2024 results with sales of $525 million, a decrease of 10% compared to the prior year. Earnings per share (EPS) were $0.51, and non-GAAP EPS was $0.96. The company faced headwinds from destocking and soft demand in consumer-facing markets.

Ashland reported Q2 2024 sales of $575 million, a 5% decrease year-over-year, but net income increased to $120 million. Adjusted EBITDA was $126 million, exceeding the previously issued outlook range. The company is experiencing demand normalization within the Personal Care and Specialty Additives segments.

Ashland reported sales of $473 million, a 10% decrease compared to the prior-year quarter. Net income was $26 million, and income from continuing operations was $28 million, or $0.54 per diluted share. Adjusted EBITDA was $70 million. Cash flows provided by operating activities totaled $201 million, and ongoing free cash flow was $66 million.

Ashland Inc. reported Q4 fiscal year 2023 results with sales of $518 million, down 18% year-over-year. The company experienced a net loss of $4 million, or $0.07 per diluted share. Adjusted income from continuing operations excluding intangibles amortization expense was $21 million, or $0.41 per diluted share. Adjusted EBITDA was $74 million, down 50% year-over-year.

Ashland reported sales of $546 million, a 15% decrease compared to the prior-year quarter. Net income was $50 million, and adjusted EBITDA was $133 million, down 24% from the prior-year quarter. The company's financial results were consistent with the earnings update issued on June 28, and the company continues to manage inventory levels in response to customer destocking actions.

Ashland reported sales of $603 million, consistent with the prior-year quarter. Net income was $91 million, and income from continuing operations was $92 million. The company updated its financial outlook for fiscal year 2023, expecting sales in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $580 million to $610 million.

Ashland reported sales of $525 million, a 3% increase year-over-year. Net income was $40 million, and income from continuing operations was $42 million, or $0.76 per diluted share. Adjusted EBITDA was $108 million, up 2% from the prior year.

Ashland reported a 7% increase in sales to $631 million for the fourth quarter of fiscal year 2022. Net income rose to $57 million, or $1.04 per diluted share, while income from continuing operations reached $60 million, or $1.09 per diluted share. Adjusted EBITDA was $147 million, a slight decrease of 1% from the prior-year quarter. The company issued its outlook for fiscal year 2023, expecting sales to be in the range of $2.5 billion to $2.7 billion, and adjusted EBITDA to be in the range of $600 million to $650 million.

Ashland's Q3 2022 results showed strong sales growth of 19% year-over-year, driven by disciplined pricing and improved product mix. Adjusted EBITDA increased by 35% compared to the prior-year quarter. The company raised its outlook for sales and Adjusted EBITDA for the full fiscal year 2022.

Ashland reported a strong second quarter with sales up 19% year-over-year, driven by disciplined pricing and improved product mix. Net income increased significantly due to a gain on the sale of the Performance Adhesives business. The company continues to expect sales in the range of $2.25 billion to $2.35 billion and adjusted EBITDA in the range of $550 million to $570 million for fiscal year 2022.

Ashland reported sales of $512 million, a 9% increase from the prior-year quarter. Net income was $48 million, down from $56 million in the prior-year quarter. The company faced global logistics challenges and cost inflation, which impacted earnings.

Ashland reported strong Q4 2021 results with sales increasing by 12% to $591 million, driven by strong demand, enhanced pricing, and the Schülke & Mayr acquisition. Net income rose to $43 million, and adjusted EBITDA reached $149 million. The company also issued its fiscal year 2022 outlook, expecting further growth.

Ashland reported sales of $637 million, up 11% year-over-year, with net income of $80 million. Strong demand was partially offset by weakness in hand-sanitizer ingredients and Avoca. Global supply-chain and logistics disruptions also limited the company’s ability to meet all customer demand.

Ashland reported sales of $598 million, a decrease of 2% compared to the prior-year period. Net income was $41 million, and adjusted EBITDA was $134 million, down from $142 million in the prior-year quarter. The company faced challenges from weather-related events in the U.S. Gulf Coast and changing consumer behavior due to the global pandemic.

Ashland reported sales of $552 million, up four percent from the prior-year quarter. Net income was $56 million, or $0.91 per diluted share. Cash flows provided by operating activities totaled $106 million, and free cash flows totaled $76 million.

Ashland reported flat sales of $609 million compared to the prior-year quarter. Net income was $5 million, or $0.07 per diluted share. Adjusted income from continuing operations excluding intangibles amortization expense was $76 million, or $1.25 per diluted share. Adjusted EBITDA was $154 million, and free cash flow was $116 million.

Ashland reported sales of $574 million, a 10% decrease compared to the prior-year quarter. Net income was $37 million, and adjusted EBITDA increased to $143 million. The company saw improved performance in its consumer business units, particularly in pharmaceutical excipients and additives for hand sanitizers, while industrial businesses showed signs of recovery in June.

Ashland reported a 9% decrease in sales to $610 million compared to the prior-year quarter. The net loss was $582 million, primarily due to a non-cash goodwill impairment charge. Adjusted income from continuing operations was $52 million, consistent with the prior-year quarter, and adjusted EBITDA was $142 million, also consistent with the prior year.

Ashland reported sales of $533 million, a 7% decrease compared to the prior-year quarter. Net income was $32 million, and adjusted EBITDA was $88 million. The company faced challenges due to weaker demand in consumer and industrial end markets, as well as the impact of a prior-year business loss.